Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
98% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. GHDX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GHDX' s Cash to Debt Range Over the Past 10 Years
Min: 6.08  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.76
GHDX's Equity to Asset is ranked higher than
73% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. GHDX: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
GHDX' s Equity to Asset Range Over the Past 10 Years
Min: -3.02  Med: 0.78 Max: 0.89
Current: 0.76
-3.02
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
96% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.71 vs. GHDX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GHDX' s Interest Coverage Range Over the Past 10 Years
Min: 80.08  Med: 10000.00 Max: 9999.99
Current: No Debt
80.08
9999.99
F-Score: 2
Z-Score: 12.17
M-Score: -3.28
WACC vs ROIC
7.84%
-91.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.84
GHDX's Operating margin (%) is ranked lower than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. GHDX: -11.84 )
Ranked among companies with meaningful Operating margin (%) only.
GHDX' s Operating margin (%) Range Over the Past 10 Years
Min: -106.14  Med: -7.43 Max: 4.01
Current: -11.84
-106.14
4.01
Net-margin (%) -11.59
GHDX's Net-margin (%) is ranked lower than
57% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.57 vs. GHDX: -11.59 )
Ranked among companies with meaningful Net-margin (%) only.
GHDX' s Net-margin (%) Range Over the Past 10 Years
Min: -99.13  Med: -7.61 Max: 3.81
Current: -11.59
-99.13
3.81
ROE (%) -22.98
GHDX's ROE (%) is ranked lower than
60% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.04 vs. GHDX: -22.98 )
Ranked among companies with meaningful ROE (%) only.
GHDX' s ROE (%) Range Over the Past 10 Years
Min: -52.9  Med: -15.45 Max: 7.79
Current: -22.98
-52.9
7.79
ROA (%) -17.65
GHDX's ROA (%) is ranked lower than
58% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.95 vs. GHDX: -17.65 )
Ranked among companies with meaningful ROA (%) only.
GHDX' s ROA (%) Range Over the Past 10 Years
Min: -43.22  Med: -12.16 Max: 6.18
Current: -17.65
-43.22
6.18
ROC (Joel Greenblatt) (%) -99.85
GHDX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -13.49 vs. GHDX: -99.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GHDX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -475.73  Med: -72.55 Max: 74.51
Current: -99.85
-475.73
74.51
Revenue Growth (3Y)(%) 6.70
GHDX's Revenue Growth (3Y)(%) is ranked higher than
59% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. GHDX: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GHDX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.15 Max: 136.5
Current: 6.7
0
136.5
» GHDX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GHDX Guru Trades in Q1 2015

Jim Simons 36,900 sh (+202.46%)
Chuck Royce 33,000 sh (unchged)
» More
Q2 2015

GHDX Guru Trades in Q2 2015

Jim Simons 267,200 sh (+624.12%)
Chuck Royce 33,000 sh (unchged)
» More
Q3 2015

GHDX Guru Trades in Q3 2015

Chuck Royce 35,000 sh (+6.06%)
Jim Simons 233,800 sh (-12.50%)
» More
Q4 2015

GHDX Guru Trades in Q4 2015

Chuck Royce 66,500 sh (+90.00%)
Jim Simons 289,600 sh (+23.87%)
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 357.14
GHDX's Forward P/E is ranked lower than
100% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.80 vs. GHDX: 357.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.45
GHDX's P/B is ranked lower than
79% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. GHDX: 6.45 )
Ranked among companies with meaningful P/B only.
GHDX' s P/B Range Over the Past 10 Years
Min: 3.3  Med: 7.16 Max: 14.28
Current: 6.45
3.3
14.28
P/S 3.08
GHDX's P/S is ranked higher than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.23 vs. GHDX: 3.08 )
Ranked among companies with meaningful P/S only.
GHDX' s P/S Range Over the Past 10 Years
Min: 2.17  Med: 4.09 Max: 20.43
Current: 3.08
2.17
20.43
EV-to-EBIT -23.77
GHDX's EV-to-EBIT is ranked lower than
99.99% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.90 vs. GHDX: -23.77 )
Ranked among companies with meaningful EV-to-EBIT only.
GHDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -791  Med: -16.40 Max: 514.8
Current: -23.77
-791
514.8
EV-to-EBITDA -30.00
GHDX's EV-to-EBITDA is ranked lower than
99.99% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.72 vs. GHDX: -30.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
GHDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -251.2  Med: -14.80 Max: 939.6
Current: -30
-251.2
939.6
Current Ratio 3.35
GHDX's Current Ratio is ranked higher than
58% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. GHDX: 3.35 )
Ranked among companies with meaningful Current Ratio only.
GHDX' s Current Ratio Range Over the Past 10 Years
Min: 3.35  Med: 4.78 Max: 15.83
Current: 3.35
3.35
15.83
Quick Ratio 3.35
GHDX's Quick Ratio is ranked higher than
66% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. GHDX: 3.35 )
Ranked among companies with meaningful Quick Ratio only.
GHDX' s Quick Ratio Range Over the Past 10 Years
Min: 3.35  Med: 4.78 Max: 15.83
Current: 3.35
3.35
15.83
Days Sales Outstanding 47.19
GHDX's Days Sales Outstanding is ranked higher than
68% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.21 vs. GHDX: 47.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
GHDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.3  Med: 31.93 Max: 47.19
Current: 47.19
23.3
47.19
Days Payable 58.26
GHDX's Days Payable is ranked higher than
56% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.98 vs. GHDX: 58.26 )
Ranked among companies with meaningful Days Payable only.
GHDX' s Days Payable Range Over the Past 10 Years
Min: 14.62  Med: 46.44 Max: 92.94
Current: 58.26
14.62
92.94

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.02
GHDX's Price/Net Cash is ranked lower than
69% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.13 vs. GHDX: 18.02 )
Ranked among companies with meaningful Price/Net Cash only.
GHDX' s Price/Net Cash Range Over the Past 10 Years
Min: 3.64  Med: 12.37 Max: 23.16
Current: 18.02
3.64
23.16
Price/Net Current Asset Value 9.19
GHDX's Price/Net Current Asset Value is ranked lower than
61% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.92 vs. GHDX: 9.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GHDX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.53  Med: 9.43 Max: 14.73
Current: 9.19
3.53
14.73
Price/Tangible Book 6.44
GHDX's Price/Tangible Book is ranked lower than
63% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. GHDX: 6.44 )
Ranked among companies with meaningful Price/Tangible Book only.
GHDX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.3  Med: 7.21 Max: 11.06
Current: 6.44
3.3
11.06
Price/Projected FCF 7.52
GHDX's Price/Projected FCF is ranked lower than
90% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. GHDX: 7.52 )
Ranked among companies with meaningful Price/Projected FCF only.
GHDX' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.46  Med: 6.22 Max: 37.9
Current: 7.52
4.46
37.9
Price/Median PS Value 0.75
GHDX's Price/Median PS Value is ranked higher than
70% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. GHDX: 0.75 )
Ranked among companies with meaningful Price/Median PS Value only.
GHDX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.84  Med: 0.91 Max: 3.87
Current: 0.75
0.84
3.87
Earnings Yield (Greenblatt) (%) -4.21
GHDX's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. GHDX: -4.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GHDX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.21  Med: 0.90 Max: 1.3
Current: -4.21
-4.21
1.3

More Statistics

Revenue(Mil) $287
EPS $ -1.03
Beta0.79
Short Percentage of Float8.24%
52-Week Range $20.05 - 35.79
Shares Outstanding(Mil)32.98

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 325 366 422
EPS($) -0.54 0.08 0.21
EPS without NRI($) -0.54 0.08 0.21

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:SZSE:300244, TSE:4544, NAS:CPHD, SZSE:300463, NAS:NEOG, NAS:KANG » details
Traded in other countries:G7H.Germany,
Genomic Health Inc was incorporated in Delaware in August 2000. It is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company is engaged in the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company's Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The Company provides its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ, or DCIS and a Genomic Prostate Score, or GPS, for prostate cancer. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the "oncotype" of a tumor. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. Its Oncotype DX prostate cancer test measures the level of expression of 17 genes across four biological pathways to predict prostate cancer aggressiveness in men with low risk disease. It has a direct commercial presence with employees and consultants in the United States and certain other countries, and its Oncotype DX breast and colon cancer tests are also available outside of the United States through a network of distributors. The Company faces competition from companies that offer products or have conducted research to profile genes, gene expression or protein expression in breast, colon or prostate cancer, including public companies such as, GE Healthcare, a business unit of General Electric Company, Hologic, Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Novartis AG, Qiagen N.V. and Response Genetics, Inc., and many private companies. It faces competition from commercial laboratories with distribution networks for diagnostic tests, such as Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated. The Company holds 32 issued patents in the United States and 65 issued patents outside of the United States. As a clinical reference laboratory, the Company is subject to hold certain federal, state and local licenses, certifications and permits to conduct its business.
» More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Jan 19 2011 

More From Other Websites
Genomic Health to Announce First Quarter 2016 Financial Results and Host Conference Call on... Apr 27 2016
Genomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : April 8, 2016 Apr 08 2016
Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : April 7,... Apr 07 2016
Genomic Health (GHDX): Moving Average Crossover Alert Apr 01 2016
Genomic Health: Bleak Q4 on Lower Margins, Higher Costs Mar 18 2016
Genomic's Oncotype DX Positive in 5-Year Breast Cancer Trial Mar 15 2016
Woman Says Cancer Test Company Fired Her For Having Cancer Mar 15 2016
GENOMIC HEALTH INC Financials Mar 15 2016
Hedge Funds Are Hoarding Shares of These 5 Small-Caps Mar 11 2016
Genomic Health Announces Five-year Outcomes from International 'PlanB' Study Demonstrating the... Mar 11 2016
GENOMIC HEALTH INC Files SEC form 10-K, Annual Report Mar 09 2016
German National Cancer Guidelines Distinguish Oncotype DX® as First and Only Multi-gene Breast... Mar 09 2016
Genomic Health Breast Cancer Assay Positive in PlanB Trial Mar 02 2016
Genomic Health to Present at the Cowen and Company 36th Annual Health Care Conference Mar 02 2016
Journal of Clinical Oncology Publishes Prospective Outcomes Results from Large International Trial... Mar 01 2016
GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 22 2016
Genomic Health, Inc. Earnings Analysis: Q4, 2015 By the Numbers Feb 12 2016
Genomic Health Q4 Loss Wider than Expected, Revenues Up Feb 11 2016
Edited Transcript of GHDX earnings conference call or presentation 10-Feb-16 9:30pm GMT Feb 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK